Patents by Inventor Andreas Rådevik

Andreas Rådevik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTISENSE OLIGONUCLEOTIDE FOR ORAL ADMINISTRATION
    Publication number: 20230357768
    Abstract: A pharmaceutical composition comprising A) one or more ASO or a pharmaceutically acceptable salt thereof; B) one or more permeation enhancer; C) one or more optional pharmaceutically acceptable excipient; and D) one or more optional coating. Said composition for use in the treatment, prevention, or amelioration of a disease associated with PCSK9 or PNPLA3 in a subject.
    Type: Application
    Filed: September 16, 2021
    Publication date: November 9, 2023
    Inventors: Anna TIVESTEN, Nigel DAVIES, Marie ELEBRING, Peter GENNEMARK, Mariagrazia MARUCCI, Niclas CLEMMENSEN, Hanna MATIC, Okky PUTRA, Pratik Pankaj UPADHYAY, Katrin WALTER, Lloyd TILLMAN, Luis DELLAMARY, Andreas RÅDEVIK
  • Millicapsule formulations comprising polyunsaturated free fatty acids
    Patent number: 10512611
    Abstract: Capsular dosage forms containing polyunsaturated fatty acid (PUFA) compositions are provided herein. In certain embodiments, unit dosage forms comprising a plurality of millicapsules containing a PUFA composition therein are provided as well as their methods of use and manufacture. In certain embodiments, capsular dosage forms are provided herein that include a unit dosage form comprising a plurality of millicapsules containing a polyunsaturated free fatty acid substantially in free acid form. In some embodiments, the PUFA composition is Epanova®.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: December 24, 2019
    Assignee: Omthera Pharmaceuticals Inc.
    Inventors: Hironori Kubota, Etienne Thierry Charles Rogeau, Tohru Amemiya, Julien Georges Meissonnier, Anders Gillis Holmén, Andreas Rådevik, Hans Carlsson, Bengt Staffan Schantz
  • MILLICAPSULE FORMULATIONS COMPRISING POLYUNSATURATED FREE FATTY ACIDS
    Publication number: 20180325829
    Abstract: Capsular dosage forms containing polyunsaturated fatty acid (PUFA) compositions are provided herein. In certain embodiments, unit dosage forms comprising a plurality of millicapsules containing a PUFA composition therein are provided as well as their methods of use and manufacture. In certain embodiments, capsular dosage forms are provided herein that include a unit dosage form comprising a plurality of millicapsules containing a polyunsaturated free fatty acid substantially in free acid form. In some embodiments, the PUFA composition is Epanova®.
    Type: Application
    Filed: February 19, 2016
    Publication date: November 15, 2018
    Applicant: OMTHERA PHARMACEUTICALS INC.
    Inventors: Hironori KUBOTA, Etienne Thierry CHARLES ROGEAU, Toru AMEMIYA, Julien Georges MEISSONNIER, Anders Gillis HOLMÉN, Andreas RÅDEVIK, Hans CARLSSON
  • Process for the manufacturing of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-indole-5-carbonitrile 701
    Patent number: 8101750
    Abstract: The present invention relates to a new process for the manufacture of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile as a free base and pharmaceutically acceptable salts thereof, particularly the 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile citrate, and to new intermediates prepared in said process suitable for large scale manufacturing of said compound.
    Type: Grant
    Filed: April 17, 2008
    Date of Patent: January 24, 2012
    Assignee: AstraZeneca AB
    Inventors: Vern Delisser, Martin Hedberg, Annette Jansson, Andreas Rådevik, Per Ryberg, Swantje Thiering